Description
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. At the Magnetic Resonance business line, it is our mission to enable healthcare professionals and researchers to detect disease earlier and treat it more effectively – for the ultimate benefit of the patient. As the undisputed market leader, we are harnessing the full potential of digital technologies such as artificial intelligence to contribute to a more sustainable future for healthcare and, most importantly, to enable high-quality MR imaging.
Role with PROBE
Within the PROBE project, our company contributes specialized expertise in quantitative cartilage assessment, with a particular focus on advanced cartilage segmentation. Our role centers on supporting the consortium regarding imaging-based biomarkers by providing both methodological guidance and state-of-the-art segmentation capabilities. We bring in our expertise together with our cartilage segmentation software Chondral Quant that delivers reliable and reproducible quantification of cartilage morphology. In addition to supplying this tool, we provide guidance on best practice implementation, including workflow integration, interpretation of quantitative outputs, and optimization of segmentation performance for diverse imaging datasets. By combining our software solutions with domain knowledge, we aim to support the consortium in achieving robust, clinically meaningful cartilage biomarkers that advance the goals of the PROBE project.
